Zepbound Explained — The New Weight Loss Drug - The Numbers Don't Lie

Join AI host Julia Cartwright as she breaks down the groundbreaking SURMOUNT clinical trials for tirzepatide (Zepbound). We cover the landmark data showing average weight loss of 21% at the highest dose, with 57% of participants losing over 20% of body weight—results previously seen only with bariatric surgery, fundamentally reshaping obesity medicine's possibilities. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.